Report cover image

A Biologics Market, By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, and Other Products), By Application (Cancer, Infectious Diseases

Publisher Coherent Market Insights
Published Jan 19, 2023
Length 170 Pages
SKU # CMI17712841

Description

Biologics Market, By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, and Other Products), By Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Other Applications), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Biologics are medicines developed from blood, proteins, viruses, or living organisms, and are used to prevent, treat, and cure many health conditions. Biologics are widely used to prevent, diagnose, treat, or cure infectious, autoimmune, and chronic diseases. Biologics offer most effective means to treat a variety of medical conditions that presently have no other treatments available.

Market Dynamics:

Increase in burden of infectious, autoimmune, and chronic diseases, rise in demand for biologics, increasing demand and higher acceptability for innovative therapies, increase in number of clinical trials, and increase in research and development are major factors expected to drive growth of the global biologics market during the forecast period.

For instance, in February 2022, the U.S. Food and Drug Administration (FDA) accepted to review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for Abrilada as an interchangeable biosimilar to Humira for patients with moderate to severe rheumatoid arthritis.

Moreover, in March 2022, TG Therapeutics Inc. announced that USFDA extended the Prescription Drug User Fee Act (PDUFA) goal date to June 25, 2022, for the Biologics License Application for ublituximab as a treatment for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Key features of the study:
  • This report provides in-depth analysis of the global biologics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global biologics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Novartis AG, AstraZeneca PLC, Bayer AG, Sanofi SA, Pfizer Inc., Merck & Co., Johnson and Johnson, GlaxoSmithKline PLC, Amgen Inc., AbbVie Inc., F. Hoffmann-La Roche AG, and Eli Lilly and Company, among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biologics market.
Detailed Segmentation:
  • Global Biologics Market, By Product:
  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Hormones/Proteins
  • Cellular-based Biologics
  • Gene-based Biologics
  • Other Products
  • Global Biologics Market, By Application:
  • Cancer
  • Infectious Diseases
  • Autoimmune Diseases
  • Other Applications
  • Global Biologics Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
  • Company Profiles:
  • Novartis AG
  • AstraZeneca PLC
  • Bayer AG
  • Sanofi SA
  • Pfizer Inc.
  • Merck & Co.
  • Johnson and Johnson
  • GlaxoSmithKline PLC
  • Amgen Inc.
  • AbbVie Inc.
  • F.Hoffmann-La Roche AG
  • Eli Lilly and Company

Table of Contents

170 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Product
Market Snapshot, By Application
Market Snapshot, By Geography
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
High prevalence of infectious and autoimmune diseases
High capital investment and stringent regulatory process
Growing demand and higher acceptability for innovative therapies
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Global Biologics Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Biologics Market, By Product, 2017-2028, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 – 2028
Segment Trends
Monoclonal Antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Vaccines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Recombinant Hormones/Proteins
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Cellular-based Biologics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Gene-based Biologics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Other Products
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
6. Global Biologics Market, By Application, 2017-2028, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 – 2028
Segment Trends
Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Infectious Diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Autoimmune Diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Other Applications
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
7. Global Biologics Market, By Geography, 2017-2028, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 – 2028
Segment Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Middle East and Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Rest of World
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
8. Competitive Landscape
Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca PLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bayer AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi SA
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson and Johnson
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GlaxoSmithKline PLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Amgen Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AbbVie Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
F. Hoffmann-La Roche AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Analyst Views
9. Section
Research Methodology
About us
*Browse 24 market data tables and 28 figures on "Global Biologics Market” - forecast t2028

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us